Northern Kentucky Eye Center Medicare Supplier Location: 5522 Taylor Mill Rd, Taylor Mill, Kentucky 41015 Phone: (859) 581-7200 |
News Archive
Presidio Pharmaceuticals, Inc. today announced progress with its HCV antiviral drug discovery and development programs. A primary company objective is to advance multiple potent and safe inhibitors that target multiple HCV proteins and provide pan-genotypic coverage, as we believe such combination therapies will more adequately address the global medical need in the future.
One third of hypertrophic cardiomyopathy cases in Finland are caused by one of the four major mutations, a new study from the University of Eastern Finland and Kuopio University Hospital shows.
The Obama administration has granted "dozens" of waivers that will allow insurers and companies - most notably McDonald's - to continue offering health benefits that do not meet new health law requirements in an effort "to stave off threats by some health insurers to abandon markets, drop out of the business altogether or refuse to sell certain policies," The New York Times reports.
Using the Hazard Analysis of Critical Control Points (HACCP) framework, researchers assessed the risk and mitigation strategies for universities with students returning to campus. The methodology allowed a rapid response to curb disease transmission with continuing education.
When published results are systematically tracked for drug trials registered with ClinicalTrials.gov, those from industry-funded trials are the likeliest to be favorable to the drug in question, report researchers at Children's Hospital Boston. Publishing in the August 3 issue of the Annals of Internal Medicine, the researchers call for more public disclosure about clinical drug trials at their outset to reduce the possibility of bias in the findings.
› Verified 4 days ago